Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) Director Spencer Berthelsen sold 8,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, June 15th. The stock was sold at an average price of $73.49, for a total transaction of $587,920.00. Following the completion of the transaction, the director directly owned 156,013 shares in the company, valued at $11,465,395.37. This represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ionis Pharmaceuticals Stock Performance
Shares of IONS opened at $74.12 on Friday. Ionis Pharmaceuticals, Inc. has a 12 month low of $36.45 and a 12 month high of $86.74. The stock has a fifty day moving average price of $74.89 and a 200-day moving average price of $77.53. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. The firm has a market cap of $12.25 billion, a PE ratio of -35.81 and a beta of 0.37.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm had revenue of $246.09 million during the quarter, compared to analysts’ expectations of $195.56 million. During the same quarter last year, the firm earned ($0.93) EPS. The business’s quarterly revenue was up 86.4% on a year-over-year basis. Equities research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.64 earnings per share for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Research Report on IONS
Institutional Trading of Ionis Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in IONS. Grandfield & Dodd LLC boosted its holdings in Ionis Pharmaceuticals by 0.4% in the fourth quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock valued at $2,992,000 after purchasing an additional 146 shares during the last quarter. Checchi Capital Advisers LLC lifted its holdings in shares of Ionis Pharmaceuticals by 3.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 4,429 shares of the company’s stock valued at $333,000 after buying an additional 157 shares during the period. Wedmont Private Capital lifted its holdings in shares of Ionis Pharmaceuticals by 3.2% in the 4th quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock valued at $460,000 after buying an additional 173 shares during the period. Prospera Financial Services Inc boosted its stake in shares of Ionis Pharmaceuticals by 3.9% in the fourth quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock worth $376,000 after buying an additional 178 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Ionis Pharmaceuticals by 2.6% during the fourth quarter. MetLife Investment Management LLC now owns 9,674 shares of the company’s stock worth $765,000 after acquiring an additional 246 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Featured Stories
- Five stocks we like better than Ionis Pharmaceuticals
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
